Premium
Penetration of Ertapenem Into Different Pulmonary Compartments of Patients Undergoing Lung Surgery
Author(s) -
Burkhardt Olaf,
MajcherPeszynska Jolanta,
Borner Klaus,
Mundkowski Ralf,
Drewelow Bernd,
Derendorf Hartmut,
Welte Tobias
Publication year - 2005
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270005276117
Subject(s) - ertapenem , medicine , bronchoalveolar lavage , cmax , lung , pharmacokinetics , perioperative , pneumonia , in vivo , anesthesia , antibiotics , surgery , urology , chemistry , meropenem , biology , biochemistry , microbiology and biotechnology , antibiotic resistance
Ertapenem is approved for the treatment of community‐acquired pneumonia (CAP), but its in vivo penetration into lung tissue (LT), epithelial lining fluid (ELF), and alveolar cells (AC) is unknown. Fifteen patients undergoing thoracotomy were treated with 1 g intravenously for perioperative prophylaxis. Bronchoalveolar lavage was performed 1, 3, and 5 hours after ertapenem infusion. Normal LT was sampled at the time of lung extraction. Blood was collected before and at different time points up to 24 hours after infusion. Mean concentrations of ertapenem in plasma, ELF, and AC were at 1.0 hour, 63.1, 4.06, 0.004 mg/L; at 3.0 hours, 39.7, 2.59, 0.003 mg/L; and at 5.0 hours, 27.2, 2.83, 0.007 mg/L. Mean (range) concentration in LT was 7.60 (2.5–19.4) mg/kg tissue 1.5 to 4.5 hours after infusion. In plasma, ertapenem exhibited a C max of 94.7 ± 23.3 mg/L and an AUC 0‐last of 501.1 ± 266.3 mg•h/L. These results, combined with the reported (MIC) 90 of most CAP bacteria, support the previously observed clinical efficacy of ertapenem in the treatment of CAP.